Figure 4

Influences of AFP on the expression of Src and pAKT(Ser473) in L-02 cells, L-02-X(stable transfected with pcDNA3.1-HBx) cells and PLC/PRF/5 cells. A, Expression of AFPR in L-02, L-02-X and PLC/PRF/5 cells were analyzed by Western blotting. B, L-02, L-02-X or PLC/PRF/5 cells were treated with AFP(20 mg/L), Ly294002(20 μM) or co-treated with AFP(20 mg/L) and Ly294002(20 μM) for 24 hours respectively, expression of Src and pAKT(Ser473) in these cells were analyzed by Western blotting, right column images represented the protein densitometry value compare with internal control β-actin or total AKT ratio. *P < 0.05 vs treated with AFP, Ly294002 or co-treated with AFP and Ly294002 groups; **P <0.01 vs untreated, treated with Ly294002 or co-treated with AFP and Ly294002 groups. C, L-02, L-02-X or PLC/PRF/5 cells were treated with AFP(20 mg/L), GDC0941(10 μM) or co-treated with AFP(20 mg/L) and GDC0941(10 μM) for 24 hours respectively, expression of Src and pAKT(Ser473) in these cells were analyzed by Western blotting, right column images represented the protein densitometry value compare with internal control β-actin or total AKT ratio. *P < 0.05 vs treated with AFP, GDC0941 or co-treated with AFP and GDC0941 groups; **P <0.01 vs untreated, treated with GDC0941 or co-treated with AFP and GDC0941 groups. The images were representation of three reduplicate experiments.